-
1.发明授权公开(公告)号：US07858745B2
公开(公告)日：2010-12-28
申请号：US11760399
申请日：2007-06-08
Applicant: Arnon Lavie , Manfred Konrad , Farhad Ravandi
Inventor： Arnon Lavie , Manfred Konrad , Farhad Ravandi
CPC classification number: B82Y5/00 , A61K47/6815 , A61K47/6899 , C07K16/2803 , C07K2319/30 , C12N9/1205
Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
Abstract translation: 本发明提供了通过特异性工程化的酶提高前药的效率的方法，所述酶具有增强的对癌症化疗中使用的核苷类似物的活性，并将酶递送到患者中的特定靶细胞。 本发明还提供具有这种增强活性的修饰的脱氧胞苷激酶（dCK）突变体。 此外，本发明提供可以在体内或体外特异性递送至白血病胚胎细胞的抗体缀合的酶。
-
2.发明申请公开(公告)号：US20070258968A1
公开(公告)日：2007-11-08
申请号：US11760399
申请日：2007-06-08
Applicant: Arnon Lavie , Manfred Konrad , Farhad Ravandi
Inventor： Arnon Lavie , Manfred Konrad , Farhad Ravandi
CPC classification number: B82Y5/00 , A61K47/6815 , A61K47/6899 , C07K16/2803 , C07K2319/30 , C12N9/1205
Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
Abstract translation: 本发明提供了通过特异性工程化的酶提高前药的效率的方法，所述酶具有增强的对癌症化疗中使用的核苷类似物的活性，并将酶递送到患者中的特定靶细胞。 本发明还提供具有这种增强活性的修饰的脱氧胞苷激酶（dCK）突变体。 此外，本发明提供可以在体内或体外特异性递送至白血病胚胎细胞的抗体缀合的酶。
-
3.发明授权公开(公告)号：US07419811B2
公开(公告)日：2008-09-02
申请号：US10791155
申请日：2004-03-01
Applicant: Arnon Lavie , Manfred Konrad , Farhad Ravandi
Inventor： Arnon Lavie , Manfred Konrad , Farhad Ravandi
CPC classification number: B82Y5/00 , A61K47/6815 , A61K47/6899 , C07K16/2803 , C07K2319/30 , C12N9/1205
Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
Abstract translation: 本发明提供了通过特异性工程化的酶提高前药的效率的方法，所述酶具有增强的对癌症化疗中使用的核苷类似物的活性，并将酶递送到患者中的特定靶细胞。 本发明还提供具有这种增强活性的修饰的脱氧胞苷激酶（dCK）突变体。 此外，本发明提供可以在体内或体外特异性递送至白血病胚胎细胞的抗体缀合的酶。
-
4.发明申请公开(公告)号：US20050008648A1
公开(公告)日：2005-01-13
申请号：US10791155
申请日：2004-03-01
Applicant: Arnon Lavie , Manfred Konrad , Farhad Ravandi
Inventor： Arnon Lavie , Manfred Konrad , Farhad Ravandi
IPC: A61K39/395 , A61K47/48 , C07K16/28 , C12N9/00 , C12N9/12
CPC classification number: B82Y5/00 , A61K47/6815 , A61K47/6899 , C07K16/2803 , C07K2319/30 , C12N9/1205
Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
Abstract translation: 本发明提供了通过特异性工程化的酶提高前药的效率的方法，所述酶具有增强的对癌症化疗中使用的核苷类似物的活性，并将酶递送到患者中的特定靶细胞。 本发明还提供具有这种增强活性的修饰的脱氧胞苷激酶（dCK）突变体。 此外，本发明提供可以在体内或体外特异性递送至白血病胚胎细胞的抗体缀合的酶。
-
-
-
Search Results
4
records
(took 0.014 seconds)
